Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models

Neoplasia (United States)

Volumn 14, Issue 11, 2012, Pages 1005-1014

  Cassell, Andre ^a   Freilino, Maria L ^a   Lee, Jessica ^a   Barr, Sharon ^b   Wang, Lin ^a   Panahandeh, Mary C ^a   Thomas, Sufi M ^c   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL) IMIDAZO [5, 1 F] [1, 2, 4] TRIAZIN 7 YL) CYCLOHEXANECARBOXYLIC ACID; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN P70; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR VOLUME;

EID: 84869152615     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121212     Document Type: Article

References (53)

1. He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, and Grandis JR (1998). Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 90, 1080-1087.
2. Ang KK, Berkey BA, Tu X, Zhang H-Z, Katz R, Hammond EH, Fu KK, and Milas L (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62, 7350-7356.
3. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, et al. (2006). Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24, 4170-4176.
4. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, and Baselga J (2007). Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25, 2171-2177.
5. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, et al. (2007). Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 25, 2178-2183.
6. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, and Siu LL (2004). Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22, 77-85.
7. Zhang Q, Thomas SM, Lui VWY, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, and Grandis JR (2006). Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci USA 103, 6901-6906.
8. Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, and Grandis JR (2006). Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 66, 11831-11839.
9. Kisfalvi K, Eibl G, Sinnett-Smith J, and Rozengurt E (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69, 6539-6545.
10. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, and Griffin G (2006). Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5, 2676-2684.
11. She Q-B, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, and Rosen N (2010). 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18, 39-51.
12. Rozengurt E (2007). Mitogenic signaling pathways induced by G proteincoupled receptors. J Cell Physiol 213, 589-602.
13. Rozengurt E, Sinnett-Smith J, and Kisfalvi K (2010). Crosstalk between insulin/ insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16, 2505-2511.
14. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, and Sabatini DM (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev Cell 11, 859-871.
15. Wang L, Harris TE, Roth RA, and Lawrence JC (2007). PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282, 20036-20044.
16. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, and Fingar DC (2010). mTOR Ser-2481 autophosphorylation monitors mTORCspecific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285, 7866-7879.
17. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, et al. (2009). Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114, 1618-1627.
18. Gingras A-C, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, and Sonenberg N (1999). Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13, 1422-1437.
19. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, and Su B (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137.
20. Yang Q, Inoki K, Ikenoue T, and Guan K-L (2006). Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20, 2820-2832.
21. Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
22. Yang Q, Inoki K, Kim E, and Guan K-L (2006). TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci USA 103, 6811-6816.
23. Treins C, Warne PH, Magnuson MA, Pende M, and Downward J (2009). Rictor is a novel target of p70 S6 kinase-1. Oncogene 29, 1003-1016.
24. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, and Hall MN (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128.
25. Krause C, Carey T, Ott R, Hurbis C, McClatchey K, and Regezi J (1981). Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 107, 703-710.
26. Gioanni J, Fischel J, Lambert J, Demard F, Mazeau C, Zanghellini E, Ettore F, Formento P, Chauvel P, and Lalanne C (1988). Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol 24, 1445-1455.
27. Rangan S (1972). A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29, 117-121.
28. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, and Grandis JR (2003). Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22, 6183-6193.
29. Chou T and Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55.
30. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, and Faivre S (2008). Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 62, 305-313.
31. Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, et al. (2011). Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 10, 1394-1406.
32. Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, and Platanias LC (2011). Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 17, 4378-4388.
33. Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, and Gutkind JS (2008). A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res 68, 1144-1153.
34. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JKS, Ampil F, Glass J, and Nathan C-AO (2009). Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 8, 2255-2265.
35. Nathan C-AO, Amirghahari N, Sibley D, Rong X, Khodavandi M, Zhou H, and Smith M (2004). In vivo and in vitro effect of CCI-779 a rapamycin analogue on HNSCC. AACR Meet Abstr 2004, 850-851.
36. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, and Gutkind JS (2009). Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res 2, 27-36.
37. Bhola N (2009). Investigation of the Mechanisms and Therapeutic Implications of Crosstalk between G-protein-coupled Receptors and the Epidermal Growth Factor Receptor in HNSCC (PhD Dissertation). University of Pittsburgh, Pittsburgh, PA. Available from Dissertations & Theses @ University of Pittsburgh.
38. Bhola NE, Thomas SM, Freilino ML, Joyce SC, Sahu A, Maxwell J, Argiris A, Seethala RR, and Grandis JR (2011). Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res 17, 4996-5004.
39. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. (2006). mTOR inhibition induces upstreamreceptor tyrosine kinase signaling and activates Akt. Cancer Res 66, 1500-1508.
40. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, Chen R, Clark DP, Forastiere A, and Hidalgo M (2007). Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96, 952-959.
41. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, et al. (2010). Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16, 205-213.
42. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, et al. (2011). PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10, 558-565.
43. Inoki K, Li Y, Zhu T, Wu J, and Guan K-L (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4, 648-657.
44. Sato T, Nakashima A, Guo L, Coffman K, and Tamanoi F (2010). Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29, 2746-2752.
45. García-Martínez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, and Alessi DR (2009). Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421(pt 1), 29-42.
46. Vakana E, Sassano A, and Platanias LC (2010). Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy 6, 966-967.
47. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, and Lichtenstein A (2010). Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560-4568.
48. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, and Gray NS (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284, 8023-8032.
49. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, et al. (2010). Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCRABL-expressing leukemic cells. Proc Natl Acad Sci USA 107, 12469-12474.
50. Gupta M, Hendrickson AEW, Yun SS, Han JJ, Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL, et al. (2012). Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-487.
51. Zhang N, Erjala K, Kulmala J, Qiu X, Sundvall M, Elenius K, and Grénman R (2009). Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 92, 388-392.
52. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, and McDonald DM (2011). Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 71, 1573-1583.
53. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, et al. (2011). The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322.